)
)
Alaunos Therapeutics Investor Relations Material
Latest events
Q1 2023
Alaunos Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Alaunos Therapeutics Inc
Access all reports
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company, which develops adoptive TCR engineered T-cell therapies. The company is developing ALNS-1VJ001, a CD19 targeted adoptive cell therapy, to treat B-cell malignancies and lymphomas. Its lead product candidate ALNS-1VJ001 is undergoing clinical trials as a combination therapy with bendamustine hydrochloride (Treanda) for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Alaunos Therapeutics, Inc. has strategic alliance with Merck & Co., Inc.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
TCRT
Country
🇺🇸 United States